They do seem to offer significant protection against severe illness, but the consequences of rapidly spreading infection worry many public health experts.
Author: Stephanie Nolen
A Times correspondent returning from South Africa got caught up in the chaotic response to Omicron.
The Omicron variant turned my trip home from South Africa into a nightmare episode of conflicting public health orders that often seemed to have little connection to science.
How Conflicting Guidance on Travel During the Pandemic Shows Little Progress
The Omicron variant turned my trip home from South Africa into a nightmare episode of conflicting public health orders that often seemed to have little connection to science.
As Vaccines Trickle Into Africa, Zambia’s Challenges Highlight Other Obstacles
Vaccinating Africa is critical to protecting the continent and the world against dangerous variants, but supply isn’t the only problem countries face.
The Variant Hunters: Inside South Africa’s Effort to Stanch Dangerous Mutations
Scientists in a cutting-edge laboratory do part of the work. Local health workers on foot do the rest.
South African Company Nears License to Sell J. & J. Covid Shot Across Africa
The new agreement makes Aspen Pharmacare the first African company to market a Covid vaccine on the continent. But it stops short of allowing Aspen to make the ingredients in the vaccine.
South African Company Nears License to Sell J. & J. Covid Shot Across Africa
The new agreement makes Aspen Pharmacare the first African company to market a Covid vaccine on the continent. But it stops short of allowing Aspen to make the ingredients in the vaccine.
Merck Will Share Formula for Its Covid Pill With Poor Countries
The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
Gates Foundation Pledges $120 Million to Help Get Merck Covid Pills to Poor Countries
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.